Several other studies have also provided novel evidence of a critical role of IL‐17 in the progression of MAFLD, revealing that IL‐17 could accelerate high‐fat‐induced hepatic steatosis (Chackelevicius et al., 2016; Shen et al., 2017). Here, IL17A is linked to fatty liver disease.